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Abstract
The burden of disease due to influenza is not well characterized for children in developing 
countries and the effectiveness of available influenza vaccines in lower resource settings has not 
been established. We initiated a prospective, longitudinal, phase IV, household-randomized, 
controlled, observer-blinded three year study (2009–2011) in a rural community of India to 
measure the total and indirect household protective effects of immunizing children ages 6 months 
through 10 years with seasonal inactivated trivalent influenza vaccine (TIV) or a control vaccine (n 
= 3697). Active weekly surveillance was conducted year round with home visits for identification 
of febrile acute respiratory illness (FARI) conducted for all vaccine recipients and household 
members (n = 18,220). Nasal and throat swabs were collected from each FARI episode for 
influenza detection by real-time reverse transcription polymerase chain reaction. The primary 
outcome was reduction in laboratory confirmed influenza infections in the influenza vaccine 
versus control vaccine group, with secondary outcome assessing indirect effects among the entire 
study population. This report describes the study site, cluster study design, choice of study and 
control vaccines, and the initial enrollment in the study.
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1. Introduction
Although influenza disease is well characterized in both developed and developing 
countries, the epidemiology in developing countries is less well described, particularly for 
children [1–3]. Furthermore, influenza vaccine use remains very limited in many developing 
countries and the benefits of immunization in these populations have not been investigated to 
the same extent as in developed countries [4]. Policy makers may have concerns as to 
whether the potential benefits justify the cost and difficulties associated with adding a 
vaccine to their national schedules. This is particularly relevant because in contrast to the 
single or limited series of immunizations required by most childhood vaccines, influenza 
vaccines are given annually. In addition, the issue of indirect immunity has not been 
addressed in a developing country, where various factors, including malnutrition, 
overcrowding and inadequate sanitation may influence the degree of protection [5,6]. Lastly, 
understanding direct and indirect effects of influenza vaccine in these settings will help 
optimize deployment of vaccine in the face of pandemic influenza threats.
Among children less than 5 years of age in India, there are 43 million episodes of 
pneumonia and over 400,000 pneumonia deaths each year [7]. In the area in which the 
current study is ongoing, 11% of acute lower respiratory infections in young children are 
due to influenza [8].
India is considering adding new vaccines such as that for influenza to its vaccine program. 
National policy states that new vaccines would be considered based disease burden as well 
as on safety and efficacy of the vaccine [9]. Moreover, vaccine manufacturers in India have 
begun production of influenza vaccine.
The objectives of the current study are to measure the efficacy of influenza vaccine in 
reducing influenza infections among immunized children and the indirect protective effects 
for unvaccinated persons in the households of immunized children. Here we report the 
salient aspects of the planning, design, and initiation of this ongoing study in India.
2. Methods
2.1. Study site and population
The study site was in Ballabgarh, located in Faridabad in the state of Haryana in northern 
India. Three villages (Dayalpur, Atali, and Chandawli) were selected on the basis of sample 
size requirements, presence of a health facility, and proximity to the Ballabgarh health 
center. The study design and initial participation are described here, efficacy results will be 
reported later. Health care at the site was provided by the Comprehensive Rural Health 
Services Project (CRHSP), a collaborative effort between the Centre for Community 
Medicine at the All India Institute of Medical Sciences (AIIMS) in New Delhi and the state 
of Haryana. Each person in the catchment area was recorded in the CRHSP computerized 
database and has a unique health information system number. In the study villages many 
homes were in compounds that shared a courtyard which likely resulted in numerous 
interactions of children and adults. The extent of social interaction and mixing within the 
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compound seemed the most important attributes for the purposes of this study, thus all of 
those within a compound were considered as one household for randomization [10,11].
2.2. Study design
The study is prospective, controlled, participant and observer blinded and randomized by 
household. The allocation as to vaccine group was permanent for the entire study, each year 
children assigned to receive influenza vaccine will receive influenza vaccine and those 
assigned to the control poliovirus vaccine will receive poliovirus vaccine.
2.3. Sample size estimations
Power calculations were performed for both total (direct and indirect) protection of 
immunized children as well as indirect protection of unimmunized individuals in the 
households of immunized children (Table 1). For the total effect among children, it was 
assumed that the laboratory confirmed influenza attack rate would be 5% per year (or 5 per 
100 person/years) in the unvaccinated group, and we decided the minimum detectable 
effectiveness should be 50% [12]. To assess total protection, 785 households are required per 
study group for 95% power. This was based on a conservative assumption of a coefficient of 
variation of 0.25 for the rates [13]; with about 2 vaccine-eligible children per household, 
only a small proportion of households were expected to have more than one confirmed child 
case, with resulting low within-household correlation.
For the indirect effects, the level of protection was difficult to predict [14]. A recent study 
reported an indirect protective effect of 61% for influenza immunization, similar to the 
direct protective effect [6]. We anticipated the majority of the indirect protective effect 
occurs in the home and will be near or exceed 25%, which we judged would be a minimum 
effect of public health importance. With 893 households per group the study would have 
80% power for 25% effectiveness (Table 1).
2.4. Enrollment, inclusion and exclusion criteria
Subjects were approached in their homes and offered enrollment. All inhabitants of the three 
study villages were eligible to participate in the surveillance component of the study. There 
were no exclusion criteria for surveillance. Participation in the vaccine arm of the study was 
available to children 6 months through 10 years of age. Exclusion criteria from the vaccine 
groups included known allergy to eggs, hypersensitivity to the vaccines or components of 
the vaccines, acute severe febrile illness (temporary exclusion) or any other condition that 
would impose a health risk.
2.5. Randomization and blinding
Household randomization to TIV or IPV was performed by the study statistician and vaccine 
assignments were indicated in a coded fashion. All of those living within a compound were 
considered as one household for randomization. Labels were applied that showed the 
vaccine code and obscured the underlying labels of the pre-filled vaccine syringes (as 
suggested by personal communication, John Victor). The pharmacist did not participate in 
field activities or vaccine administration. Separate vaccine administrators were hired solely 
for the immunization period.
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3. Vaccination
Seasonal inactivated split-virion trivalent influenza vaccine (TIV) and trivalent inactivated 
poliovirus vaccine (IPV) are commercially available in India [15]. Oral poliovirus vaccine 
(OPV) is the vaccine in use to control poliovirus in India. However, the Indian Academy of 
Pediatrics recommends the addition of IPV to OPV [16]. Vaccine schedules and composition 
are shown (Table 2). At the initiation of the study only northern hemisphere influenza 
vaccine was available in India, it became available in the fall each year. Immunizations were 
accomplished December 2009–January 2010 (year 1), and in October–November of 2010 
and 2011.
3.1. Case definition: febrile acute respiratory illness (FARI)
FARI was used as the clinical indicator of possible influenza infection and was defined as 
reported fever and any respiratory complaint (such as cough, sore throat, nasal congestion, 
runny nose, earache, or difficulty breathing) within the past week. No documentation of 
fever or observation of other signs was required. We believed this provided increased 
sensitivity for identification of influenza illnesses, albeit at the expense of lower specificity 
[17]. However, because the primary outcome measure was laboratory confirmed influenza, 
the final measure is very specific. Each FARI episode was considered to last a maximum of 
two weeks.
3.2. Surveillance
Active surveillance was performed with weekly visits to the homes. Both vaccine and non-
vaccine participants were enrolled and under surveillance. Households that did not include 
vaccinees were expected to provide additional data as to the role of children in introducing 
influenza into their homes and risk factors for influenza. When FARI was reported subjects 
were assessed and temperature, respiratory rate, heart rate, pulse oximetry, and respiratory 
effort were recorded. FARI events were classified by World Health Organization criteria 
[18,19]. If national standards required therapy it was provided or the individuals were 
referred to the health center. As our data showed there may be year round circulation and 
bimodal peaks of influenza activity surveillance occurred year around [20].
3.3. Sample collection and processing
From each patient with FARI a throat and nasal swab were collected (nasopharyngeal swabs 
alone in infants). Samples were divided into aliquots, for influenza detection, viral culture, 
and storage. CDC real time RT-PCR protocols were used as described for influenza testing, 
these assays are highly sensitive and specific [21]. Prior to initiation of testing AIIMS 
laboratory staff received CDC training and the laboratory underwent external quality control 
assessments. Further antigenic characterization of the viruses was planned to include 
hemagglutination inhibition.
3.4. Data management
Creation of the study databases consisted of a linkage of three databases: (1) an electronic 
Rural Health Information System database with house numbers and demographic data for 
enrolled residents; (2) structured paper forms used for field data collection that were 
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optimized for optical character recognition scanning for rapid processing using TeleForm® 
software (Autonomy Inc., San Francisco, CA) and high speed scanners; and (3) an in-house 
created laboratory data base that stored all study sample testing and laboratory results. All 
sources of the data were uploaded to a secured study server that resides in India, where data 
could be downloaded and processed by the appropriate study staff both in India and in the 
USA. All forms that were scanned also had select data fields that were human verified while 
processing through TeleForm® software for data quality. All data were linked and processed 
for data quality, both individually and across data sources. Study data were maintained in 
SAS® (SAS Systems, Inc., Cary, NC) databases for data editing, maintenance and analyses.
3.5. Analysis plan
The main statistical analyses proposed are total vaccine efficacy among children 6 months–
10 years of age and indirect vaccine efficacy among non-vaccinated household contacts of 
children enrolled for vaccination [22]. Statistical significance in all our analyses will be 
determined using a two-sided 0.05 significance level. Statistical analyses will be conducted 
on a year-to-year basis as well as pooled analysis for multiple years. For the children 6 
months–10 years of age, analyses will be modified intention-to-treat, comparing those 
children who actually receive a dose of influenza vaccine (intervention households) to those 
receiving control vaccine (control households). Analyses of older household members will 
be strict intention-to-treat, in that their experience will be analyzed according to the 
allocation of the household. The influenza-vaccinated (those who receive at least one dose) 
and control vaccine individuals will be compared with respect to incidence of FARI and 
laboratory confirmed influenza. Vaccine efficacy will be estimated for children from 6 
months through 10 years of age using incidence density methods. Incidence rates of 
laboratory confirmed influenza among influenza and control vaccine recipients will be 
determined by dividing the sum of laboratory confirmed influenza episodes/total number of 
person weeks at risk. The unadjusted rate ratio (RR) of influenza will be calculated, and total 
vaccine efficacy calculated as (1 – RR) × 100%. 95% confidence intervals will be calculated, 
accounting for within-household correlation by conditioning on the total number of episodes 
and assuming a Poisson model with Pearson residual-estimated scale parameter [23]. 
Similarly, rates among individuals aged 11 years and old will be compared between 
intervention-assigned households and control-assigned households, which will yield 
estimates of the indirect effect of the intervention. For analyses in which more than 10% of 
the individuals experience more than one outcome event, we can gain further precision by 
using a generalized linear mixed model (Poisson regression with random effects) to account 
for the two levels (household and individual) of correlation.
3.6. Ethical approvals
Ethical review was provided by the AIIMS Ethics Committee and the University of Alabama 
Birmingham (UAB) Institutional Review Board. The Centers for Disease Control and 
Prevention (CDC) Institutional Review Board approved a request to rely upon the AIIMS 
Ethics Committee review. The Health Ministry Steering Committee of the Indian Council for 
Medical Research provided federal government review and approval. A Data and Safety 
Monitoring Board was established In Delhi to assess the safety of the participants. The trial 
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was enrolled in Clinical Trials Registry – India (CTRI/2010/091/001235,13-10-2010) and at 
ClinicalTrials.gov (NCT00934245).
Prior to seeking informed consent meetings were undertaken with village leaders and village 
grass-roots workers. Adults provide signed consent, for children parental consent was 
obtained, and for children 7 years of age and up assent was requested.
4. Results
High rates of enrollment were obtained for both surveillance and vaccine activities, over 
90% of the eligible population agreed to participate in surveillance (Table 3). Similarly, in 
the first year of immunization (November 2009–January 2010) among 3694 vaccine eligible 
children 80% were vaccinated completely (one or two doses depending on age) and 11% 
received one of two planned doses of vaccine (Fig. 1). Enrollment and vaccine participation 
numbers were provisional at this time as data analysis was ongoing. Two thousand eight 
hundred and six households enrolled in the study, of which 1690 households included 
children eligible to participate in the vaccine component. This provided 845 households for 
each of the two study arms, influenza and control vaccine. This met the sample size goal for 
direct effects (785 households) and was near the goal for assessing indirect effects (893 
households), as well as the goals for individual subjects as described in Methods (Table 1).
5. Discussion
This report describes the design and initiation of a study to define the indirect and total 
protective effects of immunizing children with trivalent influenza vaccine (TIV) in a rural 
community of India. The study site in Ballabgarh builds on the commitment to research 
from the AIIMS faculty members who provide primary care in the CRHSP and their rapport 
among the study population. The investigators at AIIMS, UAB, and the CDC were familiar 
with the study population and had established relationships that facilitated implementation 
of the study [8].
Cluster designs are essential for the assessment of indirect immunity following 
immunization [24]. Household randomization was chosen as it provided a sufficient number 
of units of randomization and kept the number of participants within the limits of available 
resources. Randomization at the individual level would have limited the possibility of 
detecting indirect protection in situations where there was more than one child in the house 
and not all the children received influenza vaccine. A limitation of the use of households for 
randomization was that it reduced the potential contribution of community level indirect 
effects, since not all the children in each village will receive influenza vaccine. However, 
CDC was collaborating on a village randomized trial in Senegal and that would provide 
useful information on community level effects.
There were several factors to consider in choosing a control vaccine. Age, route, and timing 
of administration needed to be compatible with that of the study vaccine. The control 
vaccine also needed to be licensed in India and not be given as a routine immunization. The 
control vaccine also should not interfere with the assessment of outcomes for the study. 
Pneumococcal, haemophilus influenzae B and hepatitis B vaccines were considered and then 
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rejected on one of the above grounds. Inactivated poliovirus vaccine was chosen as a vaccine 
that satisfied the above requirements. Furthermore, it was recommended for use in India as 
an adjunct to the national approach using oral poliovirus vaccine [16].
Influenza virus infections are frequently but not always associated with fever and respiratory 
symptoms [17]. This has been confirmed in another investigation in the study area, where 
influenza case definitions failed to identify all hospitalized patients who were infected with 
influenza virus (unpublished data, Vivek Gupta et al.). Thus our clinical criteria would not 
result in testing in all influenza infections. Similarly, and especially in young children, 
influenza might manifest as fever without other symptoms [25]. These cases too would not 
be identified in our study. As a practical matter, definitions such as FARI or influenza like 
illness are frequently used in clinical investigations of influenza.
A related issue is that the likelihood of a positive test for influenza declines over time. Peak 
virus shedding in volunteers occurs 2 days after virus challenge and usually stops by 7 days 
[26]. Therefore, weekly visits in this study might result in samples being taken when virus 
shedding had decreased. Although clinical case definitions for influenza have limitations, we 
attempted to balance these parameters by using a subjective case definition combined with a 
highly sensitive and specific virus diagnostic technique [17].
The efficacy of influenza vaccine depends in part on the antigenic match between the viruses 
in circulation vs. those used to make the vaccine [15]. The appearance of influenza 
A(H1N1)pdm09 in India posed a challenge as the seasonal vaccine formulation did not 
include the pandemic virus and monovalent influenza A(H1N1)pdm09 vaccine was not yet 
available in India. The pandemic provided a dramatic example of antigenic mismatch 
between the circulating virus and the vaccine components and emphasized the importance of 
multi-year studies of influenza vaccines. It also required a change to two doses of vaccine in 
2010 as compared to the planned single dose of vaccine.
Northern hemisphere influenza vaccine is imported into India and administered in the fall. 
The study described here used the northern hemisphere formulation. However, recent 
surveillance data showed the largest peak of influenza is in July–September during the rainy 
season in the Delhi region, with minor peaks in the winter [20]. Indian regions where 
influenza occurs during the rainy season might benefit from immunization before the 
summer using the southern hemisphere influenza vaccine due to timing of availability. 
Furthermore, for influenza viruses that are not well matched antigenically to the components 
of the vaccine, there may reduced efficacy for TIV more than four months after 
immunization [27]. This suggests immunization closer in time to the rainy season influenza 
period may offer advantages as compared to immunization in the fall of the preceding year. 
In recognition of this pattern of seasonality, we plan a future study of immunization in 
spring with southern hemisphere influenza vaccine so that these results can be as compared 
with the current study of fall immunization with northern hemisphere influenza vaccine.
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6. Conclusions
This report describes the design of an influenza vaccine study being undertaken among 
children in rural India. The study should provide valuable new data as to the potential role of 
influenza vaccines for the reduction of influenza virus disease burden in developing 
countries.
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Fig. 1. 
Flow diagram of enrollment for participation in vaccine component of study.
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Table 1
Total and indirect effect sample size estimates.
Total (assumes 50% protection) Indirect (assumes 25% protection)
Control group rate per 100 child-years 5 5
Vaccine group rate per 100 child-years 2.5 3.75
Vaccine efficacy 50% 25%
Coefficient of variation 0.25 0.25
Cluster Size 2 5
Power 95% 80%
Number of households required (clusters) 785 893
Subjects per group 1570 4465
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Table 2
Vaccine doses and schedule.
Age Dose # Doses year 1 # Planned doses years 2 and 3
Influenza vaccine
6–35 months 0.25 mla 2 1
3–8 years 0.5 mlb 2 1
9–10 years 0.5 mlb 1 1
Poliovirus vaccinec
6 months–8 years 0.5 ml 2 1
9–10 years 0.5 ml 1 1
The strains for the 2009–2010 influenza vaccine were: A/Brisbane/59/2007 (H1N1), A/Brisbane/10/2007 (H3N2)-like strain A/Uruguay/716/2007, 
and B/Brisbane/60/2008.
aVAXIGRIP Junior.
bVAXIGRIP.
c
Imovax Polio, Sanofi Pasteur India, New Delhi.
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Table 3
Age and gender of population enrolled in surveillance.
Age Total # (%) Male/female (ratio)
0–5 years 2510 (13.8) 1362/1148 (1.12)
6–18 years 4714 (25.9) 2574/2140 (1.2)
19–29 years 4068 (22.3) 2070/1998 (1.04)
30–44 years 3693 (20.3) 2023/1670 (1.21)
45–59 years 1985 (10.9) 999/986 (1.01)
60+ years 1250 (6.8) 584/666 (0.88)
Total 18,220 9612/8608 (1.12)
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